NMPA Approves Sedomin Gene Injection (Huasueling) for Severe Limb Ischemia with Ulceration

(Source: China Food and Drug Network)

Recently, the National Medical Products Administration approved BeijingNorthlandThe Setdomingji Injection (Brand Name: Huasuoling) submitted by Beijing Northland Biotechnology Co., Ltd. has been approved for marketing. It is indicated for the treatment of limb ulcers resulting from severe lower limb ischemia (such as lower extremity arteriosclerosis obliterans, thromboangiitis obliterans, and diabetic lower limb ischemia) in patients who are unsuitable for revascularization procedures or in whom surgical outcomes are suboptimal. The market launch of this product provides a new therapeutic option for these patients.

《Chinese Medicine》 Publishing House. All rights reserved. Unauthorized reproduction or use is prohibited.

(Responsible Editor: Chang Jingjie)